Novo Nordisk A/S
) has received a positive opinion from the Committee for
Medicinal Products for Human Use (CHMP) for its hemophilia A
Novo Nordisk is looking to get NovoEight approved in the EU
for the treatment and prevention of bleeding in patients with
A final decision on NovoEight should be out shortly. With the
CHMP adopting a positive opinion, we expect NovoEight to gain EU
approval. The company expects to launch the candidate in early
2014. It has also filed for approval in the U.S., Japan,
Australia and Switzerland.
The filing was based on the guardian program, enrolling about
210 patients suffering from hemophilia A. The phase III studies,
namely, guardian 1 and guardian 3, included previously treated
adults and children with severe hemophilia A. Roughly 350,000
patients across the world have hemophilia A.
We are encouraged by Novo Nordisk's progress in developing
treatments for hemophilia. Novo Nordisk also has N8-GP, a
hemophilia A candidate, whose phase III study is scheduled to
finish in the first half of 2014.
Another candidate, N9-GP, for the treatment of hemophilia B is
in phase III development. The company expects to file N9-GP for
approval in 2015, after the completion of the remaining two phase
III studies in the paradigm program.
Currently, the hemophilia market has drugs like Advate,
Xyntha, Recombinate and Kogenate FS.
Biogen Idec Inc.
) is currently looking to get its hemophilia A candidate,
Eloctate, approved in the U.S.
Novo Nordisk currently carries a Zacks Rank #2 (Buy). Other
large cap pharma stocks that look well-placed include
). Roche carries a Zacks Rank #1 (Strong Buy) while Bayer carries
a Zacks Rank #2.
BAYER A G -ADR (BAYRY): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.